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ABSTRACT
Objectives: The aim of the study was to assess clinical presentation,
endoscopic findings, antibiotic susceptibility and treatment success of
Helicobacter pylori (H. pylori) infected pediatric patients.
Methods: Between 2013 and 2016, 23 pediatric hospitals from 17 countries
prospectively submitted data on consecutive H. pylori-infected (culture
positive) patients to the EuroPedHP-Registry.
Results: Of 1333 patients recruited (55.1% girls, median age 12.6 years),
1168 (87.6%) were therapy naı̈ve (group A) and 165 (12.4%) had failed
treatment (group B). Patients resided in North/Western (29.6%), Southern
(34.1%) and Eastern Europe (23.0%), or Israel/Turkey (13.4%). Main
indications for endoscopy were abdominal pain or dyspepsia (81.2%,
1078/1328). Antral nodularity was reported in 77.8% (1031/1326) of
patients, gastric or duodenal ulcers and erosions in 5.1% and 12.8%,
respectively. Primary resistance to clarithromycin (CLA) and
metronidazole (MET) occurred in 25% and 21%, respectively, and
increased after failed therapy. Bacterial strains were fully susceptible in
60.5% of group A, but in only 27.4% of group B. Primary CLA resistance
was higher in Southern and Eastern Europe (adjusted odds ratio
[ORadj]¼ 3.44, 95% confidence interval [CI] 2.22–5.32, P< 0.001 and
2.62, 95% CI: 1.63–4.22, P< 0.001, respectively) compared with
Northern/Western Europe. Children born outside Europe showed higher
primary MET resistance (ORadj¼ 3.81, 95% CI: 2.25–6.45, P< 0.001).
Treatment success in group A reached only 79.8% (568/712) with 7 to
14 days triple therapy tailored to antibiotic susceptibility.
Conclusions: Peptic ulcers are rare in dyspeptic H. pylori-infected children.
Primary resistance to CLA and MET is markedly dependent on geographical
regions of birth and residence. The ongoing survey will show whether
implementation of the updated ESPGHAN/NASPGHAN guidelines will
improve the eradication success.
Key Words: abdominal pain, clarithromycin, endoscopy, Helicobacter
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What Is Known
 Antibiotic susceptibility and treatment adherence are
crucial for successful Helicobacter pylori eradication.
 In 2006, we reported antibiotic resistance in 1233
infected children (1033 treatment-naı̈ve) living in 14
European countries. Primary resistance rates to clar-
ithromycin and metronidazole were 20% and 23%,
respectively.
What Is New
 This second survey in 1333 culture-positive children
revealed increasing primary resistance for clarithro-
mycin (25%), but not for metronidazole (21%).
Antibiotic resistance significantly depended on geo-
graphical regions and migration status, questioning
country-based recommendations.
 Prescribed drug doses were too low, particularly for
protein pump inhibitors (PPI). Improved eradication
rates can be expected if current European Society of
Pediatric Gastroenterology, Hepatology and Nutrition/
North American Society of Pediatric Gastroenterology,
Hepatology and Nutrition guidelines are followed.
H elicobacter pylori (H. pylori) infection is acquired in earlychildhood in high and low prevalence countries and persists
in most cases, unless treated (1–4). The incidence and prevalence of
H. pylori infection decreased worldwide (5–9). Infection rates
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remain high in populations residing in or immigrating from Africa,
South and Middle America, and many Asian, Middle East, Eastern
and Southern European countries (9–12).
Chronic H. pylori infection causes gastric inflammation, but
in children compared with adults, gastritis is mostly antrum-domi-
nant with lower degree of chronicity and activity and predominant
regulatory cell infiltrate (13,14). Epidemiological and animal stud-
ies revealed an inverse relationship between early H. pylori infec-
tion and immune-mediated disease (15–17). Most infected children
are asymptomatic (18). Recurrent abdominal pain is not associated
with the infection considering age, sex and socioeconomic char-
acteristics (19). Despite rare development of peptic lesions in
children, many children with abdominal pain or dyspepsia are
investigated for H. pylori infection and treated if tested positive.
Efficacy of H. pylori eradication therapy in children
decreased. Success rates depend on the choice of antibiotics, dose
and duration of therapy, antibiotic susceptibility (20,21), and
adherence to therapy (22).
Between 1999 and 2002, we performed the first international
survey investigating antibiotic resistance rates in 1233 infected chil-
dren living in Europe (23). Fifteen years later, we initiated the
EuroPedHP registry to study clinical presentation, endoscopic find-
ings, antibiotic susceptibility, and treatment success. The interim
results had major impact on the updated management guidelines of
the North American and European Societies of Pediatric Gastroenter-
ology, Hepatology and Nutrition (NASPGHAN and ESPGHAN) (24).
METHODS
Design of the Prospective Registry
Between2013and2016,membersoftheH.pyloriworkinggroup
of ESPGHAN from 23 centers in 17 countries submitted anonymized
demographical and clinical data on H. pylori culture-positive patients.
Participating centers were from Northern (Sweden), Western (Belgium,
France, Germany, The United Kingdom, The Netherlands), Eastern
(Slovenia, Poland, Croatia, Lithuania, Hungary), Southern Europe
(Portugal, Spain, Greece, Italy), and the Middle East (Israel, Turkey).
Theethicalcommitteeof the leadingcenterat theLudwigMaximillian’s
University of Munich approved the protocol of the anonymous data
collection. In the other centers, the respective local ethical committees
granted approval whenever required. Physicians were encouraged to
follow the H. pylori management guidelines published in 2012 (25).
After interim analysis in May 2015, higher dosing and longer duration
(14 days) of treatment were recommended.
Bacterial Culture and Antibiotic Susceptibility
Testing
Antibiotic susceptibility testing was locally performed for
metronidazole, clarithromycin, and amoxicillin using E-test or disk
diffusion. Minimal inhibitory concentrations (MIC) for resistance
were defined as follows: metronidazole at least 16 mg/ml, clari-
thromycin at least 1.0 mg/ml, and amoxicillin at least 0.5 mg/ml. A
strain was considered double resistant if results for metronidazole
and clarithromycin were above breakpoints.
Statistical Analysis
The distribution of resistance to metronidazole, clarithromy-
cin, or both was compared in different strata of variables in relation
to geographical regions (Supplemental Table 1, Supplemental
Digital Content, http://links.lww.com/MPG/B866). A univariate
logistic analysis was performed including all subjects with no
missing of considered variables except for ‘‘mother’s country of
birth.’’ Odds were calculated for antibiotic resistance and presence
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of mucosal lesions. All statistically significant variables associated
with resistance or the presence of peptic ulcer or erosions (P 0.25)
in the univariate analysis were considered in the multivariate
logistic regression. Using the same samples as in the univariate
analysis, the final multivariate logistic models were adjusted for sex
and age (below and above 12 years) after applying backward
elimination. Estimated risks (odds ratio, OR) and 95% confidence
intervals (95% CI) were reported. Data were analyzed using SAS
(Statistical Analysis Software 9.4, SAS Institute Inc., Cary, NC).
RESULTS
Study Population and Patient Characteristics
Between 2013 and 2016, data on 1460 patients with biopsy-
proven, culture-positive H. pylori infection were submitted to the
EuroPedHP Registry; 127 patients were excluded because of failing
inclusion criteria or missing data (Supplemental Figure 1, Supple-
mental Digital Content, http://links.lww.com/MPG/B866). Of the
remaining 1333 children (55.1% girls, median age 12.6 years),
87.6% were treatment-naı̈ve (group A), whereas 165 (12.4%) had
failed treatment at least once (group B). Twenty-two percentage of
the children, but 34.7% (n¼ 329) of the mothers were born outside
of Europe, Turkey, or Israel (Table 1). There was an equal distri-
bution of H. pylori-infected patients reported to the registry
each year.
Indications for Endoscopy and Endoscopic
Findings of Ulcers and Erosions
Abdominal pain and dyspepsia were the indication for
endoscopy in 81.2% of patients (Table 1). Antral nodularity was
observed during endoscopy in 77.8% of patients, gastric or duode-
nal ulcers and erosions in 5.1% and 12.8% of children, respectively.
Erosions were significantly more prevalent than ulcers, with no
significant differences between group A and group B (Table 1).
Among treatment-naı̈ve children (group A), boys had a
higher risk of having ulcers or erosions than girls (Supplemental
Table 2, Supplemental Digital Content, http://links.lww.com/MPG/
B866). Children older than 12 years were more likely to have ulcers
than younger children (Supplemental Table 2, Supplemental Digital
Content, http://links.lww.com/MPG/B866). Children living in
Northern/Western Europe were 4 times more frequently reported
to have peptic ulcers compared to children living in Southern
Europe or Israel and Turkey (OR¼ 0.26, 95% CI: 0.13–0.55,
P¼ 0.0004 and OR¼ 0.24, 95% CI: 0.08–0.70, P¼ 0.009, respec-
tively) (Supplemental Table 2, Supplemental Digital Content,
http://links.lww.com/MPG/B866).
Antibiotic Susceptibility
Antimicrobial susceptibility was tested with the E-test in 771
(57.8%), with disk diffusion in 546 (41.0%), and RT-PCR in 16
(1.2%) patients.
Antibiotic Resistance in Treatment-naı̈ve
Patients (Group A)
Metronidazole
Resistance to metronidazole was detected in 20.9% (95% CI:
18.4–23.5) of the strains obtained from treatment-naı̈ve children
(primary resistance) (Table 1). In the univariate analysis, the
following risk factors were identified for a primary metronidazole
resistance: age older than 12 years, country of residence, and birth
of the child (Table 2). Children born outside of Europe had a 3.8
times higher risk (95% CI: 2.25–6.45, P< .0001) of being resistant
to MET than children born in Northern/Western Europe (Table 3).
Clarithromycin
Primary resistance to clarithromycin was detected in 24.8%
(95% CI: 22.1–27.5) of the strains (Table 1). The univariate analysis
identified 2 important risk factors for primary clarithromycin
resistance: region of residence and region of birth of the child
(Table 2). Children living in Southern or Eastern Europe had a 3.4
and 2.6 times increased risk for primary clarithromycin resistance,
respectively, compared with children living in Northern/Western
Europe (Table 4).
Double Resistance
Primary resistance against both, clarithromycin and metro-
nidazole, was found in 5.8% of the strains (57/976) (Table 1).
Amoxicillin
Resistance to amoxicillin (AMO) was a rare event (1.2%) in
the cohort, with a slight increase in group B compared with group A
patients (P¼ 0.024) (Table 1).
Antibiotic Resistance After Failed Treatment
(Group B)
Out of 165 patients with treatment failure, the majority were
born and lived in Southern Europe, whereas their mothers were also
more likely to be born in Southern Europe (Table 1). The proportion of
patients infected with strains susceptible to both CLA and MET was
significantly lower in group B (27.4%) compared with group A (60.5%)
(P< 0.0001) (Table 1). The chance to harbor a resistant strain increased
after failed treatment, for amoxicillin from 0.9% to 3.3% (P¼ 0.024),
for metronidazole from 20.9% to 52.4% (P< 0.0001), for clarithro-
mycin from 24.8% to 47.6% (P< 0.0001), and for double resistance
from 5.8% to 27.4% (P< 0.0001) (Table 1).
Factors Associated With Antibiotic Resistance
in Treatment-naı̈ve Patients
The comparison of antibiotic susceptibility in the 4 geo-
graphical regions demonstrated marked differences in the primary
antibiotic resistance for both CLA and MET. CLA had the highest
primary resistance rate in Southern Europe (36.7%) and the lowest
in Northern/Western Europe (13.6%) (Supplemental Figure 3, Sup-
plemental Digital Content, http://links.lww.com/MPG/B866). MET
had the highest primary resistance rate in children residing in Israel
or Turkey (44.1%), whereas in the other regions, resistance ranged
from 14.2% to 20.5%. After failed therapy (group B), antibiotic
resistance increased for both antibiotics in all regions, but because
of the small numbers in some of the subgroups, interpretations
should be done with caution.
Treatment
Treatment regimens were prescribed tailored to antibiotic
susceptibility. The majority of the patients received standard triple
therapy ranging from 7 to 14 days’ duration, whereas 14% (116/
828) were treated with sequential therapy for 10 days. A small
proportion received other therapy regimens. During the 4-year
period, the median daily dose of protein pump inhibitors (PPI)
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had increased from 1.05 mg/kg body weight (2013) to 1.24 mg/kg
(2016) and of amoxicillin from 46.6 mg/kg (2013) to 57.8 mg/kg
(2016) (Supplemental Figure 4, Supplemental Digital Content,
http://links.lww.com/MPG/B866). There was a minor increase in
the median dose of clarithromycin and metronidazole over the 4
years. The duration of treatment increased from 7 to 10 to 14 days in
the majority of patients throughout the study, particularly after the
interim analysis in May 2015 (Supplemental Figure 5, Supplemen-
tal Digital Content, http://links.lww.com/MPG/B866).
Eradication Success
Treatment outcome was available in 76.2% (1016/1333) of
all patients. Among treatment-naı̈ve patients infected with fully
TABLE 1. Patient characteristics and clinical presentation (N¼1333)
Group A Group B
All patients before treatment after treatment failed
Factors (N¼ 1333) No. (%) (n¼ 1168) No. (%) (n¼ 165) No. (%) P-valuey
Demographical characteristics
Female 735 (55.1) 646 (55.3) 89 (53.9) 0.741
Age group (years), N U 1333 0.492
Age <12 605 (45.4) 526 (45.0) 79 (47.9)
Age 12 728 (54.6) 642 (55.0) 86 (52.1)
Country of residence

, N U 1333 0.0015
Northern/Western Europe 394 (29.6) 343 (29.4) 51 (30.9)
Southern Europe 455 (34.1) 384 (32.9) 71 (43.0)
Eastern Europe 306 (23.0) 287 (24.6) 19 (11.5)
Israel & Turkey 178 (13.4) 154 (13.2) 24 (14.5)
Country of birth

, N U 1118 0.0001
Northern/Western Europe 240 (21.5) 206 (21.2) 34 (23.3)
Southern Europe 399 (35.7) 331 (34.1) 68 (46.6)
Eastern Europe 226 (20.2) 216 (22.2) 10 (6.8)
Asia, Africa, America & Middle East 253 (22.6) 219 (22.5) 34 (23.3)
Mother’s country of birth

, N U 947 <.0001
Northern/Western Europe 50 (5.3) 38 (4.6) 12 (10.4)
Southern Europe 347 (36.6) 290 (34.9) 57 (49.6)
Eastern Europe 221 (23.3) 213 (25.6) 8 (7.0)
Asia, Africa, America & Middle East 329 (34.7) 291 (35.0) 38 (33.0)
Diagnostic year, N U 1333 0.199
2016 335 (25.1) 299 (25.6) 36 (21.8)
2015 342 (25.7) 302 (25.9) 40 (24.2)
2014 325 (24.4) 288 (24.7) 37 (22.4)
2013 331 (24.8) 279 (23.9) 52 (31.5)
Endoscopic findings
Indication for endoscopy, N U 1328 0.225
Abdominal pain 793 (59.7) 679 (58.4) 114 (69.1)
Dyspepsia incl. nausea, vomiting 285 (21.5) 252 (21.7) 33 (20.0)
Anemia 54 (4.1) 51 (4.4) 3 (1.8)
Celiac disease 31 (2.3) 28 (2.4) 3 (1.8)
GI-bleeding 28 (2.1) 27 (2.3) 1 (0.6)
GERD, reflux 21 (1.6) 19 (1.6) 2 (1.2)
IBD 9 (0.7) 8 (0.7) 1 (0.6)
Eosinophilic esophagitis 6 (0.5) 5 (0.4) 1 (0.6)
Others: weight loss, diarrhea etc. 101 (7.6) 94 (8.1) 7 (4.2)
Antral nodularity, N U 1326 1031 (77.8) 898 (77.3) 133 (80.6) 0.346
Ulcers, N U 1325 67 (5.1) 60 (5.2) 7 (4.2) 0.610
Erosions, N U 1325 170 (12.8) 152 (13.1) 18 (10.9) 0.430
Results of antibiotic susceptibility testing
Metronidazole resistance, N U 1126 282 (25.0) 205 (20.9) 77 (52.4) <.0001
Clarithromycin resistance, N U 1131 314 (27.8) 244 (24.8) 70 (47.6) <.0001
Amoxicillin resistance, N U 1000 12 (1.2) 8 (0.9) 4 (3.3) 0.024
Metronidazole and Clarithromycin resistance - Susceptibility subgroups, N U 1122 <.0001
MET-S/CLA-S 630 (56.1) 590 (60.5) 40 (27.4)
MET-S/CLA-R 212 (18.9) 183 (18.8) 29 (19.9)
MET-R/CLA-S 183 (16.3) 146 (15.0) 37 (25.3)
MET-R/CLA-R 97 (8.6) 57 (5.8) 40 (27.4)
N represents total number of available data for each factor in the cohort.
Country distribution was given in Supplemental Table 1, http://links.lww.com/MPG/B866.
yP-values refer to comparison between group A (before treatment) and group B (after treatment failed) obtained by the Pearson’s Chi-square test.
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susceptible strains, triple therapy for 14 days showed a higher
eradication success than for a shorter duration of 7 to 10 days
(85% vs 75.6% respectively, P¼ 0.03) (Supplemental Table 3,
Supplemental Digital Content, http://links.lww.com/MPG/
B866). No significant difference was detected by comparing
triple therapy with different duration in other susceptibility
groups. The eradication success did not achieve the treatment
goal of 90% eradication rate in any subgroup (Supplemental
TABLE 2. Univariate analysis of factors associated with metronidazole and clarithromycin resistance among pediatric patients not previously
treated for Helicobacter pylori infection
MET susceptibility, N¼ 797 CLA susceptibility, N¼ 801
MET resistant CLA resistant
Factors (n¼ 180) OR (95% CI) P-valuey (n¼ 210) OR (95% CI) P-valuey
Gender
Female 103 1 116 1
Male 77 0.92 (0.66 to 1.29) 0.642 94 1.03 (0.75 to 1.42) 0.847
Age group (years)
Age <12 64 1 79 1
Age 12 116 1.45 (1.03 to 2.04) 0.035 131 1.33 (0.96 to 1.84) 0.084
Country of residence

Northern/Western Europe 52 1 35 1
Southern Europe 39 0.61 (0.39 to 0.97) 0.035 100 3.48 (2.25 to 5.38) <.0001
Eastern Europe 45 1.15 (0.73 to 1.82) 0.538 58 2.66 (1.66 to 4.27) <.0001
Israel & Turkey 44 2.79 (1.70 to 4.60) <.0001 17 1.18 (0.63 to 2.23) 0.603
Country of birth

Northern/Western Europe 27 1 25 1
Southern Europe 37 0.87 (0.51 to 1.50) 0.623 96 3.43 (2.10 to 5.61) <.0001
Eastern Europe 47 1.71 (1.01 to 2.89) 0.046 63 2.86 (1.70 to 4.80) <.0001
Asia, Africa, America & Middle East 69 4.01 (2.40 to 6.72) <.0001 26 1.17 (0.65 to 2.13) 0.604
Mother’s country of birth

Northern/Western Europe 6 1 9 1
Southern Europe 30 0.69 (0.27 to 1.81) 0.455 94 2.04 (0.92 to 4.54) 0.080
Eastern Europe 50 1.68 (0.66 to 4.30) 0.280 58 1.33 (0.59 to 3.00) 0.495
Asia, Africa, America & Middle East 64 1.93 (0.76 to 4.88) 0.166 30 0.47 (0.20 to 1.11) 0.084
Diagnostic year
2016 54 1 57 1
2015 34 0.54 (0.33 to 0.87) 0.012 50 0.79 (0.51 to 1.24) 0.304
2014 49 0.79 (0.51 to 1.23) 0.296 51 0.76 (0.49 to 1.18) 0.221
2013 43 0.88 (0.55 to 1.40) 0.592 52 1.01 (0.64 to 1.57) 0.983
Ulcers
No 169 1 199 1
Yes 11 1.48 (0.72 to 3.06) 0.290 11 1.20 (0.58 to 2.48) 0.619
Odds ratios (OR) with 95% confidence intervals (95% CI) obtained from the univariate analysis are given. Analyses were performed with complete datasets
with no missing values in covariates, excepted the variable ‘‘mother’s country of birth.’’
Country distribution was given in Supplemental Table 1, http://links.lww.com/MPG/B866.
yP-values obtained from the Wald Chi-Square Test for the significance of OR.
TABLE 3. Final logistic regression model for metronidazole resistance among pediatric patients not previously treated for Helicobacter pylori
infection and no missing data for all of the factors considered in the univariate analysis (n¼797)
Factors Unadjusted OR Adjusted OR (95% CI) P-valuey
Gender (Male vs. Female) 0.92 0.93 (0.65 to 1.32) 0.682




Southern Europe 0.87 0.85 (0.50 to 1.46) 0.551
Eastern Europe 1.71 1.66 (0.98 to 2.81) 0.061
Asia, Africa, America & Middle East 4.01 3.81 (2.25 to 6.45) <.0001
Unadjusted odds ratios (OR) were obtained from the univariate analysis.
Adjusted odds ratios (OR) with 95% confidence intervals (95% CI) obtained from the multivariate logistic regression model with sex and age group (below or
above 12 years old) are given. Analyses were performed with complete datasets with no missing values in covariates.
Country distribution was given in Supplemental Table 1, http://links.lww.com/MPG/B866.
yP-values obtained from the Wald chi-square test for the significance of adjusted OR.
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Table 3, Supplemental Digital Content, http://links.lww.com/
MPG/B866).
DISCUSSION
Our analysis of the EuroPedHP survey data collected over 4-
years disclose problems in the management of H. pylori-infected
children and allow suggestions for improvement. The number of
children included in this survey (n¼ 1333) is comparable with the
previous 15 years ago (n¼ 1233) (23). The primary antibiotic
resistance rates are high with large differences between geograph-
ical regions. Resistance rates are also related to migrant status. The
rate of peptic ulcers in our cohort was low (5.1%). Prescribed
treatments markedly differed, and the anticipated eradication rate
of 90% was not reached, even in treatment-naı̈ve children. The
causes are multifactorial and other factors, such as adherence to
therapy, dosing of the drugs, number of biopsies taken to capture
strains with different antibiotic susceptibility in the stomach
should be addressed.
With respect to antibiotic susceptibility, our cohort is repre-
sentative of infected children residing in Europe including Israel
and Turkey (Istanbul area). To account for the uneven distribution
of patients from different countries, the study population was
clustered in 4 geographical regions, which are similar in the
accessibility and prescription behavior of antibiotics (Supplemental
Table 1, Supplemental Digital Content, http://links.lww.com/MPG/
B866). Patients from Southern Europe contributed a slightly higher
percentage whereas there were fewer patients from Israel and
Turkey. Selection and reporting bias are unlikely, as all centers
prospectively reported every child with culture-positive H. pylori
infection. Reliable data on previous eradication therapy were
obtained from parents and referring physicians. The low ulcer rate
argues against a selection bias with preferential testing children
with abnormal endoscopic findings. Most European pediatric
gastroenterologist take routine gastric and duodenal biopsies during
upper endoscopy. Indication for endoscopy were unspecific symp-
toms, such as abdominal pain and dyspepsia in 4 out of 5 patients,
whereas objective alarm signs, such as bleeding or anemia were rare
(6.2%).
Compared with our previous survey (23), this registry
included more detailed and structured reporting of endoscopic
findings. The high rate of antral nodularity (78%) confirms previous
pediatric series (26). Antral nodularity is almost pathognomonic to
H. pylori-infected children, but not related to the presence of
symptoms (27). The ulcer rate of 4% in children below 12 years
of age was equal to the previous survey, whereas the current rate in
teenagers was lower than 15 years back (6% vs 10%, respectively)
(23). Teenage boys were more likely to have ulcers than girls
pointing to either a lower threshold for endoscopy in girls or a
higher exposure to environmental risk factors like tobacco, alcohol,
or ulcerogenic drugs in adolescent boys. Our finding that children
living in Northern/Western Europe had a 4 times increased
chance of ulcer diagnosis may be because of the small number
of ulcers found. Also, indication for endoscopy differs between
countries depending on expectations of parents, reimbursement
systems, use of noninvasive tests and referral for endoscopy based
on a positive test result. In Northern/Western countries, children
born to immigrant mothers were overrepresented, and immigrant
status was related to peptic ulcer disease. This association could be
related to different extrinsic or intrinsic factors, like referral for
endoscopy or differences in genetic host or bacterial virulence
factors.
With respect to primary antibiotic susceptibility, we noticed
that metronidazole resistance decreased over the last 15 years in
Eastern Europe (from 23.8% to 20.4%) (23) and Southern Europe
(from 22.3% to 14.2%) (23). Clarithromycin resistance in Southern
Europe, however, further increased, from 32.6% to 36.7% (23). In
Eastern Europe, the clarithromycin resistance rate increased by 9%
(from 17.5% to 26.3%) (23). Israel and Turkey showed a distinct
pattern with a high metronidazole resistance rate (44.1%) but
moderate rates for clarithromycin (16.5%).
As in the previous survey, being born outside of Europe was
associated with an almost 4 times higher risk of harboring a
metronidazole-resistant strain (OR¼ 3.81 in this vs OR¼ 2.42
in the previous survey). As the mother is the main source
of infection (28), this finding is likely explained by the high
use of metronidazole in Africa, the Middle East, and Asia. For
clarithromycin resistance, there was a trend for a lower risk in
younger children. The strongest association with clarithromycin
resistance was the country of residence, confirming the positive
relationship between a macrolides prescribed for benign infections
and increasing resistant rates in Southern and Eastern Europe
in adults (29). Restricting prescriptions for macrolides in
Belgium resulted in the decreased clarithromycin resistance rates
of H. pylori strains from children 10 years later (30). This indicates
that intervention programs to reduce antibiotic use in common
colds (31) or the antibiotic stewardship initiative may decrease
antibiotic resistance within a population including H. pylori-
infected children.
Treating H. pylori in pediatric patients is a challenge as
bismuth-based combination drugs and second line antibiotics
including levofloxacin and rifabutin are not licensed. Therefore,
TABLE 4. Final logistic regression model for clarithromycin resistance among pediatric patients not previously treated for Helicobacter pylori
infection and no missing data for all of the factors considered in the univariate analysis (n¼801)
Factors Unadjusted OR Adjusted OR (95% CI) P-valuey
Gender (Male vs. Female) 1.03 1.15 (0.83 to 1.60) 0.407




Southern Europe 3.48 3.44 (2.22 to 5.32) <.0001
Eastern Europe 2.66 2.62 (1.63 to 4.22) <.0001
Israel & Turkey 1.18 1.11 (0.59 to 2.10) 0.749
Unadjusted odds ratios (OR) were obtained from the univariate analysis.
Adjusted odds ratios (OR) with 95% confidence intervals (95% CI) obtained from the multivariate logistic regression model with gender and age group
(below or above 12 years old) are given. Analyses were performed with complete datasets with no missing values in covariates.
Country distribution was given in Supplemental Table 1, http://links.lww.com/MPG/B866.
yP-values obtained from the Wald chi-square test for the significance of adjusted OR.
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a high primary success rate is even more important in children
compared with adults. To avoid repeated antibiotic exposures and
spreading of resistant strains after failed treatment, pediatric
guidelines recommended against the test and treat strategy
(24,25,32). The clear recommendation for treating infected chil-
dren is given when gastric or duodenal peptic lesions are present.
There is no evidence that symptomatic children with gastritis only
have an immediate benefit of being treated (15). Applying the test
and treat strategy to a pediatric population with an assumed H.
pylori prevalence rate of 10%, would require noninvasive testing
in 200 children and exposure to triple therapy in 20 of them in
order to benefit 1 child with ulcer. Recent consensus reports
recommend for adults to search for infected persons and treat
them prior development of intestinal metaplasia and dysplasia to
prevent gastric cancer (33,34). This does not apply to Pediatrics
(35). In children, endoscopy should be restricted to those with
symptoms suggesting organic disease. If H. pylori infection is
detected during endoscopy and therapy is anticipated, the choice
of antibiotics should be tailored to susceptibility testing (24,25).
This strategy is superior and more cost effective compared with
empiric therapy (36) with less burden to patients and their
families by avoiding further endoscopies and antibiotic usage
in this vulnerable population.
The strength of our study is the prospective recruitment of a
large number of unselected patients with culture-proven infection
from different European countries, the structured reporting of
birthplace of child and mother, indications for endoscopy, macro-
scopic findings, antibiotic susceptibility, and outcome data. No such
data are available from North America where susceptibility testing
prior therapy is rare. The collection period of 4 years and applica-
tion of the same analysis as in the previous survey allowed
comparison of findings almost 15 years apart.
This survey has several limitations: An uneven distribution of
patients from different countries due to the multicentric method,
allowing only an evaluation by geographic regions. Susceptibility
testing was not performed in a central laboratory due to financial
restrictions (29). Two methods (E-test and disc diffusion) were used
for susceptibility testing, and centers (country of residence) con-
founded the difference between the two methods. Local antibiotic
resistance breakpoints may not have been unified over years.
However, they were adjusted to the guidelines of the European
Committee of Antibiotic Susceptibility Testing (EUCAST) (37)
with AMO 0.5 mg/ml or 0.12 mg/ml, CLA 1.0 mg/ml or 0.5 mg/ml
and MET 8.0 mg/ml or 16 mg/ml, respectively (38). Nonetheless, by
comparing different breakpoints, we might overestimate a few cases
of AMO resistance, but not for MET or CLA resistance (38). Only
one biopsy was recommended for culture. This might underestimate
antibiotic resistance, since mixed infections with multiple strains
are likely to be missed (39). A large range of different drug regimens
and doses were used for treatment not allowing solid data on
treatment outcomes. Patients after failed treatment consisted only
a small portion, 12.4% of the registry. Selection bias in this sub
cohort cannot be excluded.
CONCLUSIONS
In conclusion, our results demonstrate the importance on
continuous surveillance of antibiotic susceptibility of H. pylori
strains from children considering country of living and migrant
background. We also recommend the surveillance of eradication
rates in relation to the drug regimen prescribed. Based on our data
we suggest obtaining at least two gastric biopsies (antrum and
corpus) for culture. We also suggest increasing drug doses, in
particular PPI dose, and prolonging therapy to 14 days according
to guidelines (24). We recommend improving adherence by
providing written information to caregivers (40). The ongoing
registry will show whether these measures increase eradication
rates of tailored triple therapy to at least 90%.
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